Glucocorticoid receptor agonist-1 phosphate Ala-Ala-Mal

$450$2,400

Products Details

Product Description

– Glucocorticoid receptor agonist-1 phosphate Ala-Ala-Mal is a glucocorticoid receptor agonist. Glucocorticoid receptor agonist-1 phosphate Ala-Ala-Mal can be used in anti-CD40 antibody agent conjugate (ADC). Glucocorticoid receptor agonist-1 phosphate Ala-Ala-Mal can be used for the research of inflammation and immune regulation[1].

Web ID

– HY-152121

Storage Temperature

– -20°C (Powder, sealed storage, away from moisture and light)

Shipping

– Blue Ice

Applications

– COVID-19-immunoregulation

Molecular Formula

– C47H53N4O14P

References

– [1]Adrian D. Hobson, et al. Anti-cd40 antibody drug conjugates. Patent. WO2019106608A1.

CAS Number

– 2345732-89-8

Molecular Weight

– 928.92

Compound Purity

– 98.99

SMILES

– O=P(O)(O)OCC([C@]12[C@@]3([C@@]([C@@]4([H])[C@]([C@@]5(C(CC4)=CC(C=C5)=O)C)([H])[C@H](C3)O)([H])C[C@@]1([H])O[C@@H](C6=CC=C(C=C6)CC7=CC(NC([C@H](C)NC([C@H](C)NC(CN8C(C=CC8=O)=O)=O)=O)=O)=CC=C7)O2)C)=O

Clinical Information

– No Development Reported

Research Area

– Infection; Inflammation/Immunology

Solubility

– DMSO : 100 mg/mL (ultrasonic)

Target

– Drug-Linker Conjugates for ADC;Glucocorticoid Receptor

Pathway

– Antibody-drug Conjugate/ADC Related;Immunology/Inflammation;Vitamin D Related/Nuclear Receptor

Product type

– Reference compound

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

=

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.

=